Ibudilast

Small molecule

Also known as AV411, MN-166

Approvedregulatory verdict

Evidence outlook

Approved: Asthma and post-stroke dizziness (in use in Japan for more than 20 years as of 2019) (JP)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Asthma

Also approved (2)
JP
  • Asthma and post-stroke dizziness (in use in Japan for more than 20 years as of 2019)
sec.gov
KR
  • Asthma and post-stroke dizziness (in use in Korea for more than 20 years as of 2019)
sec.gov
Featured evidence outside this drug's tracked markets:NCT04631471 · Myelopathy · Phase 3 · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT04631471 · Cambridge University Hospitals NHS Foundation Trust
2021-12-22 – 2026-09-01 · Myelopathy, Spinal Cord Diseases
What this study did
Phase 2/3 (2)
Amyotrophic Lateral Sclerosis
Other / comorbidity
NCT05513560 · University Health Network, Toronto
2023-05-31 – 2025-12-31 · Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19
What this study did
Phase 2 (10)
Amyotrophic Lateral Sclerosis
NCT02238626 · MediciNova
2014-09 – 2017-12 · Amyotrophic Lateral Sclerosis
What this study did
Other / comorbidity
NCT05414240 · University of Pennsylvania
2023-01-14 – 2027-12-31 · Alcohol Use Disorder (AUD), Alcoholism
What this study did
NCT03341078 · VA Office of Research and Development
2019-05-01 – 2025-10-15 · Methamphetamine-dependence
What this study did
NCT04429555 · MediciNova
2021-01-11 – 2024-08-07 · Pneumonia, Viral
What this study did
NCT03594435 · University of California, Los Angeles
2018-10-01 – 2023-04-19 · Alcohol Use Disorder
What this study did
NCT03489850 · University of California, Los Angeles
2018-07-16 – 2020-03-31 · Alcohol Use Disorder
What this study did
NCT01860807 · University of California, Los Angeles
2013-07 – 2017-12-31 · Methamphetamine Dependence, HIV Infection
What this study did
NCT01982942 · MediciNova
2013-11 – 2017-12 · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
What this study did
NCT01740414 · New York State Psychiatric Institute
2012-11 – 2017-05 · Opioid Abuse, Opioid Dependence
What this study did
NCT00723177 · New York State Psychiatric Institute
2008-10 – 2012-06 · Opioid-Related Disorders
What this study did
Phase 1/2 (4)
Amyotrophic Lateral Sclerosis
NCT02714036 · MediciNova
2016-05-06 – 2020-06-30 · Amyotrophic Lateral Sclerosis
What this study did
Other / comorbidity
NCT03782415 · MediciNova
2018-12-29 – 2023-08-07 · Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
What this study did
NCT01317992 · University of Adelaide
2011-04 – 2013-08 · Medication Overuse Headache
What this study did
NCT00576277 · Avigen
2006-09 – 2007-11 · Diabetic Neuropathy
What this study did
Phase 1 (5)
Other / comorbidity
NCT04054206 · MediciNova
2019-06-24 – 2020-05-31 · Healthy Volunteers
What this study did
NCT03533387 · MediciNova
2018-04-11 – 2018-09-30 · Healthy Volunteers
What this study did
NCT01389193 · Parisa Gazerani
2013-06 – 2015-12 · Migraine Headache
What this study did
NCT02025998 · University of California, Los Angeles
2013-12 – 2015-06 · Alcohol Use Disorders
What this study did
NCT01217970 · University of California, Los Angeles
2011-01 – 2013-03 · Methamphetamine-dependence, Substance Abuse
What this study did

Competitive landscape

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ibudilast: this drugPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ibudilast to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Alcohol Use Disorder (AUD), AlcoholismActive not recruiting
Est. primary completion 2026-12-31 · NCT05414240 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
Phase 2/3Amyotrophic Lateral SclerosisActive not recruiting
Est. primary completion 2027-04 · NCT04057898 · CT.gov ↗
What to watch

See the full readout calendar ↗